• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

南非和赞比亚监狱实现 90-90-90 目标:普及检测和治疗实施期间,艾滋病毒检测和抗逆转录病毒治疗的虚拟横断面覆盖情况。

Reaching for 90:90:90 in Correctional Facilities in South Africa and Zambia: Virtual Cross-Section of Coverage of HIV Testing and Antiretroviral Therapy During Universal Test and Treat Implementation.

机构信息

Department of Medicine, Johns Hopkins University, Baltimore, MD.

The Aurum Institute, Johannesburg, South Africa.

出版信息

J Acquir Immune Defic Syndr. 2024 Aug 15;96(5):465-471. doi: 10.1097/QAI.0000000000003456.

DOI:10.1097/QAI.0000000000003456
PMID:38985444
Abstract

BACKGROUND

People in correctional settings are a key population for HIV epidemic control. We sought to demonstrate scale-up of universal test and treat in correctional facilities in South Africa and Zambia through a virtual cross-sectional analysis.

METHODS

We used routine data on 2 dates: At the start of universal test and treat implementation (time 1, T1) and 1 year later (time 2, T2). We obtained correctional facility census lists for the selected dates and matched HIV testing and treatment data to generate virtual cross-sections of HIV care continuum indicators.

RESULTS

In the South African site, there were 4193 and 3868 people in the facility at times T1 and T2; 43% and 36% were matched with HIV testing or treatment data, respectively. At T1 and T2, respectively, 1803 (43%) and 1386 (36%) had known HIV status, 804 (19%) and 845 (21%) were known to be living with HIV, and 60% and 56% of those with known HIV were receiving antiretroviral therapy (ART). In the Zambian site, there were 1467 and 1366 people in the facility at times T1 and T2; 58% and 92% were matched with HIV testing or treatment data, respectively. At T1 and T2, respectively, 857 (59%) and 1263 (92%) had known HIV status, 277 (19%) and 647 (47%) were known to be living with HIV, and 68% and 68% of those with known HIV were receiving ART.

CONCLUSIONS

This virtual cross-sectional analysis identified gaps in HIV testing coverage, and ART initiation that was not clearly demonstrated by prior cohort-based studies.

摘要

背景

在押人员是艾滋病毒疫情控制的重点人群。我们试图通过虚拟的横断面分析,展示南非和赞比亚惩教设施中普遍检测和治疗的扩大规模。

方法

我们使用了两个日期的常规数据:在普遍检测和治疗实施开始时(时间 1,T1)和一年后(时间 2,T2)。我们获得了选定日期的惩教设施普查名单,并将 HIV 检测和治疗数据与之匹配,以生成 HIV 护理连续体指标的虚拟横断面。

结果

在南非现场,T1 和 T2 时设施中分别有 4193 人和 3868 人;分别有 43%和 36%的人匹配了 HIV 检测或治疗数据。T1 和 T2 时,分别有 1803 人(43%)和 1386 人(36%)已知 HIV 状况,804 人(19%)和 845 人(21%)已知患有 HIV,60%和 56%的已知 HIV 患者正在接受抗逆转录病毒治疗(ART)。在赞比亚现场,T1 和 T2 时设施中分别有 1467 人和 1366 人;分别有 58%和 92%的人匹配了 HIV 检测或治疗数据。T1 和 T2 时,分别有 857 人(59%)和 1263 人(92%)已知 HIV 状况,277 人(19%)和 647 人(47%)已知患有 HIV,68%和 68%的已知 HIV 患者正在接受 ART。

结论

这种虚拟的横断面分析发现了 HIV 检测覆盖范围和 ART 起始方面的差距,这在之前基于队列的研究中没有明确显示。

相似文献

1
Reaching for 90:90:90 in Correctional Facilities in South Africa and Zambia: Virtual Cross-Section of Coverage of HIV Testing and Antiretroviral Therapy During Universal Test and Treat Implementation.南非和赞比亚监狱实现 90-90-90 目标:普及检测和治疗实施期间,艾滋病毒检测和抗逆转录病毒治疗的虚拟横断面覆盖情况。
J Acquir Immune Defic Syndr. 2024 Aug 15;96(5):465-471. doi: 10.1097/QAI.0000000000003456.
2
Universal test-and-treat in Zambian and South African correctional facilities: a multisite prospective cohort study.赞比亚和南非教养机构的普遍检测与治疗:多地点前瞻性队列研究。
Lancet HIV. 2020 Dec;7(12):e807-e816. doi: 10.1016/S2352-3018(20)30188-0. Epub 2020 Aug 4.
3
Costs of implementing universal test and treat in three correctional facilities in South Africa and Zambia.在南非和赞比亚的三个教养所实施普遍检测和治疗的成本。
PLoS One. 2022 Aug 25;17(8):e0272595. doi: 10.1371/journal.pone.0272595. eCollection 2022.
4
"It's Not Like Taking Chocolates": Factors Influencing the Feasibility and Sustainability of Universal Test and Treat in Correctional Health Systems in Zambia and South Africa.“这并不像吃巧克力那么简单”:影响赞比亚和南非惩教卫生系统普遍检测和治疗可行性和可持续性的因素。
Glob Health Sci Pract. 2019 Jun 27;7(2):189-202. doi: 10.9745/GHSP-D-19-00051. Print 2019 Jun.
5
HIV testing and treatment coverage achieved after 4 years across 14 urban and peri-urban communities in Zambia and South Africa: An analysis of findings from the HPTN 071 (PopART) trial.在赞比亚和南非的 14 个城市和城郊社区开展 4 年后的艾滋病毒检测和治疗覆盖情况:对 HPTN 071(PopART)试验结果的分析。
PLoS Med. 2020 Apr 2;17(4):e1003067. doi: 10.1371/journal.pmed.1003067. eCollection 2020 Apr.
6
Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial.赞比亚和南非普遍艾滋病毒检测和治疗干预的成本和成本效益:来自 HPTN 071(PopART)试验的证据和预测。
Lancet Glob Health. 2021 May;9(5):e668-e680. doi: 10.1016/S2214-109X(21)00034-6. Epub 2021 Mar 12.
7
HIV prevalence and the cascade of care in five South African correctional facilities.南非五所监狱的艾滋病毒流行率和关怀传递情况。
PLoS One. 2020 Jul 2;15(7):e0235178. doi: 10.1371/journal.pone.0235178. eCollection 2020.
8
Patient-reported reasons for declining same-day antiretroviral therapy initiation in routine HIV care settings in Lusaka, Zambia: results from a mixed-effects regression analysis.赞比亚卢萨卡常规 HIV 护理环境中患者拒绝当日开始抗逆转录病毒治疗的报告原因:混合效应回归分析结果。
J Int AIDS Soc. 2020 Jul;23(7):e25560. doi: 10.1002/jia2.25560.
9
Outcomes of on-site antiretroviral therapy provision in a South African correctional facility.南非一所惩教设施中现场提供抗逆转录病毒疗法的结果。
Int J STD AIDS. 2016 Nov;27(13):1153-1161. doi: 10.1177/0956462415584467. Epub 2015 May 4.
10
What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?普及检测与治疗试验向我们揭示了实现艾滋病流行控制的道路?
J Int AIDS Soc. 2020 Feb;23(2):e25455. doi: 10.1002/jia2.25455.

引用本文的文献

1
Global, regional, and national burden and trends of HIV/AIDS among women of childbearing age from 1990 to 2021: results from Global Burden of Disease 2021.1990年至2021年全球、区域和国家育龄妇女中艾滋病毒/艾滋病的负担及趋势:全球疾病负担研究2021年结果
Front Med (Lausanne). 2025 Jul 4;12:1605092. doi: 10.3389/fmed.2025.1605092. eCollection 2025.